🚨 Novo Nordisk's Weight-Loss Drug Setback! 📉

Shares of Novo Nordisk plunged 20% after its experimental weight-loss drug, CagriSema, fell short of expectations in a late-stage trial. The trial showed a 22.7% weight reduction, below the forecasted 25%. Rival Eli Lilly capitalized, with shares jumping over 5%.

What does this mean for the competitive weight-loss drug market and Novo Nordisk’s future? Find out in this detailed breakdown.

🔔 Subscribe to Wealthy Business for insights into finance, tech, and personal growth.